Exclusive-Thermo Fisher's plant making infant RSV drug breached FDA rules, documents show
One of the largest contract drug manufacturing plants in the U.S. owned by Thermo Fisher Scientific over the past 10 years ...
Mounjaro, Zepbound shortage eases as supplies of weight loss drug rebound
Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...
Texas lawsuit alleges conspiracy to inflate insulin prices, seeks restitution
AUSTIN — Attorney General Ken Paxton sued major pharmaceutical makers and other companies Thursday, alleging they violated ...
Novo Nordisk has mitigation plans to minimize disruption from port strikes
Danish drugmaker Novo Nordisk said on Tuesday it has mitigation plans in place to minimize or prevent any disruption to its ...
Weight-Loss Drugs Are Everywhere Now. How the GLP-1 Copycats Took Over.
Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.
Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn’t a Problem.
The company is expected to present critical results from a trial of its CagriSema weight-loss injection in the fourth quarter ...
Lilly weight-loss drug copycats dealt blow as shortage ends
Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., ...
Zacks.com on MSN4h
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Insulin pen production stop: a blow to diabetes care in South Africa
Novo Nordisk's decision to stop insulin pen production poses a serious challenge to diabetes care in South Africa, where ...
This Is What Whales Are Betting On Novo Nordisk
In terms of liquidity and interest, the mean open interest for Novo Nordisk options trades today is 703.94 with a total ...
Zacks.com on MSN2d
Novo Nordisk (NVO) Stock Moves -0.89%: What You Should Know
In the closing of the recent trading day, Novo Nordisk (NVO) stood at $118.01, denoting a -0.89% change from the preceding trading day.
verywellhealth3d
Why Is Ozempic So Expensive? Novo Nordisk Blames Prescription Drug Middlemen
"Pharmacy middlemen" are to blame for the high cost of drugs like Wegovy and Ozempic, according to Novo Nordisk's CEO. Is ...